Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004
Phase of Trial: Phase IV
Latest Information Update: 13 Mar 2018
At a glance
- Drugs Denosumab (Primary)
- Indications Giant cell tumours
- Focus Adverse reactions
- Sponsors Amgen
- 08 Mar 2018 Planned End Date changed from 20 Jan 2023 to 21 Apr 2023.
- 08 Mar 2018 Planned primary completion date changed from 20 Jan 2023 to 21 Apr 2023.
- 11 Dec 2017 Status changed from not yet recruiting to recruiting.